Thus, in pancreatic NETs the mean (±SEM) proliferation rate in pasireotide-treated Men1+/− mice was significantly lower than that in PBS-treated Men1+/− mice (0.35 ± 0.03 vs 0.78 ± 0.08% per day; P < .0001; Figure 6A). The gene discussed is MEN1; the disease is pancreatic neuroendocrine tumor.